[go: up one dir, main page]

PE20081238A1 - Piperidinas sustituidas como antagonistas de hdm2 - Google Patents

Piperidinas sustituidas como antagonistas de hdm2

Info

Publication number
PE20081238A1
PE20081238A1 PE2007000844A PE2007000844A PE20081238A1 PE 20081238 A1 PE20081238 A1 PE 20081238A1 PE 2007000844 A PE2007000844 A PE 2007000844A PE 2007000844 A PE2007000844 A PE 2007000844A PE 20081238 A1 PE20081238 A1 PE 20081238A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
carbonyl
heteroaryl
substituted
cyclyl
Prior art date
Application number
PE2007000844A
Other languages
English (en)
Inventor
Yao Ma
Brian Robert Lahue
Gerald W Shipps Jr
Yaolin Wang
Stephane L Bogen
Matthew E Voss
Latha G Nair
Yuan Tian
Ronald J Doll
Zhuyan Guo
Corey O Strickland
Rumin Zhang
Mark A Mccoy
Weidong Pan
Elise M Siegel
Craig R Gibeau
Original Assignee
Schering Corp
Albany Molecular Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Albany Molecular Res Inc filed Critical Schering Corp
Publication of PE20081238A1 publication Critical patent/PE20081238A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS PIPERIDINAS SUSTITUIDAS DE FORMULA (I), EN DONDE R1 ES HETEROCICLICO, HETEROCICLENILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS CON Z; A ES O, CR8R9, S, SO2, NR10 O CO; m ES 0-2; R2 ES ARILO, HETEROARILO, CICLILO, ENTRE OTROS; R3 ES ARILO, HETEROARILO, CICLILO, HETEROCICLILO, ENTRE OTROS; R4 O R4' SON INDEPENDIENTEMENTE H, ALQUILO, ALQUENILO, ENTRE OTROS O JUNTOS PUEDEN FORMAR UN ESPIROCICLILO, ESPIROHETEROCICLILO; R5, R5', R7 Y R7' SON INDEPENDIENTEMENTE H, ALQUILO, ALQUENILO, ENTRE OTROS; R6 O R6' SON NDEPENDIENTEMENTE, H, ALQUILO, ALQUENILO, ENTRE OTROS. SON SELECCIONADOS: (1,3,4,9-TETRAHIDRO-b-CARBONIL-2-IL)-[3-(4-TRIFLUOROMETIL-FENOXI)-1-(4-TRIFLUOROMETIL-PIRIDIN-3-CARBONIL)-PIPERIDIN-3-IL]-METANONA, [4-(2-METOXI-FENIL)-PIPERAZINI-1-IL]-[3-(4-TRIFLUOROMETIL-PIRIDIN-3-CARBONIL)-PIPERIDIN-3-IL]-METANONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA HDM2 O MDM2 (DOUBLE MINUTE 2 HUMANA), SIENDO UTILES EN EL TRATAMIENTO DE CANCER, ENFEREMEDADES QUE IMPLICAN PROLIFERACION CELULAR ANORMAL O CAUSADAS POR NIVELES DE P53 INADECUADOS
PE2007000844A 2006-06-30 2007-07-02 Piperidinas sustituidas como antagonistas de hdm2 PE20081238A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81775306P 2006-06-30 2006-06-30

Publications (1)

Publication Number Publication Date
PE20081238A1 true PE20081238A1 (es) 2008-09-04

Family

ID=38656615

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000844A PE20081238A1 (es) 2006-06-30 2007-07-02 Piperidinas sustituidas como antagonistas de hdm2

Country Status (17)

Country Link
US (1) US7884107B2 (es)
EP (1) EP2035416A1 (es)
JP (1) JP2009542666A (es)
KR (1) KR20090042779A (es)
CN (1) CN101595107A (es)
AR (1) AR061726A1 (es)
AU (1) AU2007269836A1 (es)
BR (1) BRPI0713119A2 (es)
CA (1) CA2656398A1 (es)
CO (1) CO6150158A2 (es)
IL (1) IL196152A0 (es)
MX (1) MX2009000285A (es)
NO (1) NO20090469L (es)
PE (1) PE20081238A1 (es)
TW (1) TW200808781A (es)
WO (1) WO2008005268A1 (es)
ZA (1) ZA200900204B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
KR20080103996A (ko) * 2006-02-16 2008-11-28 쉐링 코포레이션 Ｅｒｋ 억제제로서 피롤리딘 유도체
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
US20080051375A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AU2008210434C8 (en) 2007-01-31 2014-03-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR20160061439A (ko) 2007-03-28 2016-05-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
CN101802615A (zh) 2007-06-15 2010-08-11 小噬菌体公司 利用增强噬菌体扩增来检测微生物的方法
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
CN102015693B (zh) * 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
US9534205B2 (en) 2008-03-17 2017-01-03 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
AR073578A1 (es) * 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
US8354444B2 (en) * 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
CA2734363C (en) * 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
NO2373784T3 (es) 2008-12-17 2018-03-24
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
BR112012008849A2 (pt) * 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
BR112012008848A2 (pt) 2009-10-16 2019-09-24 Scripps Research Inst composição, e, método in vitro ou ex vivo para induzir células de mamífero não-pluripotente em células tronco pluripotentes induzidas
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011123572A1 (en) 2010-03-31 2011-10-06 The Scripps Research Institute Reprogramming cells
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2582794B2 (en) 2010-06-15 2024-04-24 FUJIFILM Cellular Dynamics, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
DK2603600T3 (da) 2010-08-13 2019-03-04 Aileron Therapeutics Inc Peptidomimetiske makrocyklusser
FR2967072B1 (fr) 2010-11-05 2013-03-29 Univ Dundee Procede pour ameliorer la production de virus et semences vaccinales influenza
EP2651976A1 (en) * 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
KR102703637B1 (ko) 2010-12-22 2024-09-05 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
US9415103B2 (en) 2011-06-14 2016-08-16 Yeda Research And Development Co. Ltd. Combination therapy to prevent DCIS formation and progression to breast cancer
CA2841165A1 (en) 2011-07-11 2013-01-17 Cellular Dynamics International, Inc. Methods for cell reprogramming and genome engineering
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013062923A1 (en) * 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2013096150A1 (en) * 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CN102690826B (zh) * 2012-04-19 2014-03-05 山西医科大学 一种特异性降低人Aurora-A基因表达的shRNA及其应用
WO2014024993A1 (ja) * 2012-08-09 2014-02-13 国立大学法人京都大学 ピぺラジン誘導体およびその用途
US9603844B2 (en) * 2012-10-22 2017-03-28 Georgetown University Compositions and methods for treating mammary tumors
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
AU2014223547B2 (en) 2013-02-28 2017-11-16 Amgen Inc. A benzoic acid derivative MDM2 inhibitor for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
PT3013833T (pt) * 2013-06-26 2019-03-20 Univ Do Porto Oxazoloisoindolinonas derivadas de triptofanol: ativadoras de molécula pequena da p53
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
EP3164401B1 (en) 2014-07-03 2018-12-26 Boehringer Ingelheim International GmbH New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
DK3183254T3 (da) 2014-08-21 2019-08-19 Boehringer Ingelheim Int Nye spiro[3h-indol-3,2 ?-pyrrolidin]-2(1h)-one forbindelser og derivater som mdm2-p53 inhibitorer
SG11201702223UA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
WO2016074580A1 (zh) * 2014-11-14 2016-05-19 中国科学院上海生命科学研究院 一种提高cd4阳性t淋巴细胞存活率和活性的试剂及其应用
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
KR20170138534A (ko) 2015-04-21 2017-12-15 엔리벡스 테라퓨틱스 리미티드 치료적 혼주된 혈액 아폽토시스 세포 제제 및 이의 용도
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017060431A1 (en) 2015-10-09 2017-04-13 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CA3001917A1 (en) 2015-10-16 2017-04-20 Fate Therapeutics, Inc. Platform for the induction & maintenance of ground state pluripotency
TW202344686A (zh) 2015-10-30 2023-11-16 美國加利福尼亞大學董事會 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法
KR20180110141A (ko) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 암을 치료하기 위한 면역요법과 사이토카인 조절 요법의 조합
LT3490560T (lt) 2016-07-29 2025-02-25 Janssen Pharmaceutica, N.V. Būdas prostatos vėžiui gydyti naudojant niraparibą
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018055526A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
CN110505884B (zh) 2017-04-05 2022-08-12 勃林格殷格翰国际有限公司 抗癌组合疗法
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
CN108864113B (zh) * 2018-08-03 2021-08-13 南方科技大学 一种mdm2-hdac双靶点抑制剂、药物组合物及其制备和用途
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CN110628735B (zh) * 2019-04-23 2022-04-08 天津科技大学 一种5α-还原酶突变体，基因工程菌及其在高效催化5α-AD生产中的应用
KR20220020332A (ko) * 2019-06-10 2022-02-18 에이디씨 테라퓨틱스 에스에이 항-cd19 항체 약물 접합체 및 pi3k 억제제 또는 2차 제제를 포함하는 조합 요법
WO2021050702A1 (en) * 2019-09-13 2021-03-18 Dana-Farber Cancer Institute, Inc. Kdm inhibitors and uses thereof
CN113633642A (zh) * 2021-08-26 2021-11-12 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) Abt-263在制备抑制角膜移植免疫排斥反应的药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
JP2001502319A (ja) * 1996-10-15 2001-02-20 藤沢薬品工業株式会社 成長ホルモンの放出を促進するベンズオキセピン誘導体
WO1998051687A1 (en) * 1997-05-14 1998-11-19 Fujisawa Pharmaceutical Co., Ltd. Piperidino derivatives which promote growth hormone release
EP0947494A1 (en) 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
WO1999058501A1 (en) * 1998-05-11 1999-11-18 Novo Nordisk A/S Compounds with growth hormone releasing properties
GB9819860D0 (en) 1998-09-12 1998-11-04 Zeneca Ltd Chemical compounds
AR035312A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Compuestos de acido hidroxamico que contienen alquinilo como inhibidores de metaloproteinasa de matriz/tace, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de un medicamento
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
EP1294714B1 (en) * 2000-06-15 2007-08-01 Schering Corporation Thrombin receptor antagonists
US6403584B1 (en) * 2000-06-22 2002-06-11 Merck & Co., Inc. Substituted nipecotyl derivatives as inhibitors of cell adhesion
US20020099035A1 (en) * 2001-01-24 2002-07-25 Sandanayaka Vincent P. Method for preparing alpha-sulfonyl hydroxamic acid derivatives
CN100486969C (zh) 2001-12-18 2009-05-13 霍夫曼-拉罗奇有限公司 顺式-2,4,5-三苯基-咪唑啉及其在肿瘤治疗中的应用
CN1182113C (zh) * 2002-07-19 2004-12-29 中国科学院上海有机化学研究所 2，5－cis－二取代的吡咯烷衍生物、合成方法及其用途
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7632920B2 (en) * 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
DE602005011132D1 (de) 2004-05-18 2009-01-02 Hoffmann La Roche Neuartige cis-imidazoline
PL1966151T3 (pl) 2005-12-13 2012-02-29 Merck Sharp & Dohme Policykliczne pochodne indazoli jako inhibitory ERK

Also Published As

Publication number Publication date
TW200808781A (en) 2008-02-16
US20080004287A1 (en) 2008-01-03
CA2656398A1 (en) 2008-01-10
EP2035416A1 (en) 2009-03-18
BRPI0713119A2 (pt) 2012-04-17
ZA200900204B (en) 2010-01-27
IL196152A0 (en) 2009-09-22
CO6150158A2 (es) 2010-04-20
KR20090042779A (ko) 2009-04-30
US7884107B2 (en) 2011-02-08
AU2007269836A1 (en) 2008-01-10
MX2009000285A (es) 2009-06-08
CN101595107A (zh) 2009-12-02
WO2008005268A1 (en) 2008-01-10
JP2009542666A (ja) 2009-12-03
NO20090469L (no) 2009-03-27
AR061726A1 (es) 2008-09-17

Similar Documents

Publication Publication Date Title
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20091173A1 (es) Derivados de heteroarilo como antagonistas de receptor de orexina
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
EA200601849A1 (ru) 4-фениламинохиназолин-6-ил-амиды
PE20080344A1 (es) Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20061436A1 (es) Derivados de amida sustituida como inhibidores de proteina quinasa
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20121172A1 (es) Piperidinas sustituidas con actividad en la hdm2
PE20091649A1 (es) Derivados de pirrolidinilo
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
PE20091433A1 (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procedimientos para su preparacion 177
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
PE20080405A1 (es) COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE ITPKb
PE20061096A1 (es) Derivados de oxiindol como agonistas 5-ht4
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20120218A1 (es) Compuestos para el tratamiento de trastornos metabolicos

Legal Events

Date Code Title Description
FC Refusal